GlassScriptPhysician profile
Ryan J Sanderson
NPI 1295171056
$4,151.74
in general payments reported to CMS, 2019-2025
37 companies · $877 in 2025
The $877 reported for 2025 was more than what 84% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $623 · 2020: $236 · 2021: $169 · 2022: $649 · 2023: $1,067 · 2024: $531 · 2025: $877.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,293 · Education: $182.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,293.15 |
| Education | $182.24 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $672.42 | 2021-2025 | Qulipta, Ubrelvy, Synthroid |
| Novo Nordisk INC | $390.35 | 2019-2025 | Ozempic, Rybelsus, Saxenda |
| Astrazeneca Pharmaceuticals LP | $340.31 | 2019-2025 | Breztri, Airsupra |
| Abbott Laboratories | $299.78 | 2020-2025 | Ensite, Assurity, Freestyle Libre 3 |
| Glaxosmithkline, LLC. | $245.87 | 2019-2025 | Shingrix, Arexvy, Trelegy Ellipta |
| Medtronic, INC. | $214.20 | 2023-2025 | Intellis Adaptivestim |
| Lilly USA, LLC | $206.23 | 2019-2025 | Zepbound, Mounjaro, Jardiance |
| Pfizer INC. | $205.45 | 2020-2025 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $180.22 | 2023-2025 | Caplyta |
| Amgen INC. | $171.64 | 2019-2025 | Otezla, Repatha, Otezla |
| Biosense Webster, INC. | $122.11 | 2022-2023 | Carto 3 |
| Astellas Pharma US INC | $113.31 | 2019-2025 | Veozah |
| Otsuka America Pharmaceutical, INC. | $91.55 | 2025 | Rexulti |
| Vanda Pharmaceuticals INC. | $85.51 | 2024-2025 | Fanapt |
| Allergan, INC. | $84.14 | 2019-2020 |
Show all 37 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ryan Sanderson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.